



Economic Impact of Earlier Detection and Therapeutic Management of Leptomeningeal Metastases Using CNSide: A Cost-of-Care Analysis

Kelly Ondrasek,¹ Randy Goodman,^{1,2} Russ Havranek¹
¹CNSide Diagnostics, Houston, TX, USA ²T.H. CHAN School of Public Health, Cleveland, Ohio, USA

Background

- Leptomeningeal Metastases (LM) occurs in ~5-20% of patients with solid tumors; most commonly from breast, lung, and melanoma^{1,2}
- LM drives high cost and poor outcomes, often recognized late, leading to intensive use of inpatient, outpatient, and palliative services^{3,4}
- Diagnostic delay/uncertainty prolongs time to CNS-active therapy and increases preventable spend (e.g., unplanned admissions, repeat imaging)
- Claims bundling masks LM-specific spend, hindering cost attribution, forecasting, and value assessment of new diagnostics

Objectives

- To estimate late-stage (stage IV) LM costs, including drug therapy, imaging, hospitalizations, and palliative care
- To evaluate the economic and clinical impact of CNSide, a novel cerebrospinal fluid (CSF) assay platform enabling earlier, definitive LM tumor cell detection, quantification, characterization, and real-time response monitoring

Methods

- A hypothetical cost-of-care model was developed using literature, real-world data, and claims databases to estimate direct and indirect medical costs associated with late-stage LM diagnosis⁵⁻⁸
- Sensitivity analyses tested standard pathway (MRI and repeated cytology; empiric therapy) vs. a CNSide-enabled pathway (earlier definitive diagnosis, targeted therapy, quantitative monitoring)
- Key Assumptions: Adults with suspected/confirmed stage IV LM (breast, NSCLC, melanoma); 6-month life expectancy (range 4–8); 1 drug, 1 cycle/month. CNSide improves sensitivity, enables earlier diagnosis, and reduces repeat LPs/MRIs and inpatient days
- Cost ranges were applied to address bundling (LM vs. primary cancer)

Platform




Figure 1. CNSide CSF Tumor Cell (CSF-TC) Capture Platform

The CNSide workflow captures CSF-TCs from CSF using a 10-antibody cocktail, then traps them in a microfluidic device enabling quantitative tumor cell enumeration (TCE) and further analyses with fluorescence in situ hybridization (FISH) and immunocytochemistry (ICC)

Results

Take Home #1: Earlier, definitive diagnosis and better monitoring most strongly influence time on therapy; regimen choice has the biggest impact on cost

- Base-case average monthly LM cost ≈ \$119,500 over 6 months (Table 1). One-way sensitivity analysis varied single parameters to assess impact on net monthly cost (Figure 2).
- Largest Cost Drivers
 - 1) Drug cost per cycle:
 - Range tested: \$7,000–\$15,000
 - Δ vs. base: –\$18,000 to +\$30,000 (max swing \$30,000, ±16–26%)
 - 2) Treatment duration (active cycles)
 - Range tested: 4–8 cycles
 - Δ vs. base: –\$21,000 to +\$21,000 (max swing \$21,000, ±18%)

Parameter	Monthly Cost / Units
Base fixed	\$61,000
Drug cost per cycle	\$11,000
Hospital cost per event	\$20,000
Expected hospital events	1.6
Imaging cost	\$2,500
Palliative cost	\$12,500
Administrative cost per cycle	\$550
Monthly Total:	\$119,550
Life Expectancy (months):	6
6 Month Total:	\$717,300

Table 1. Cost-of-Care Model for Late-Stage (Stage IV) LM Diagnosis




Figure 2. One-Way Sensitivity Analysis: CNSide’s impact on monthly LM management costs

Results

Take-Home #2: Even with costlier targeted therapy, earlier LM confirmation plus optimized management is cost-reducing; the extent depends most on drug cost/cycle and treatment duration




Figure 3. Multi-Way Scenario Analysis: Impact of CNSide-enabled earlier LM detection and optimized management on Monthly LM management costs

Conclusions

- By enabling earlier LM confirmation and optimized, quantitatively monitored management, CNSide can plausibly reduce monthly LM-related costs by ~33-47%
- Overall spend is ultimately driven by regimen composition, including drug selection and combination strategies
- These findings underscore the need for integrating advanced diagnostic technologies to address the economic and clinical burden of LM

References

- Freret ME, Boire A. The anatomic basis of leptomeningeal metastasis. J Exp Med. Apr 1 2024;221(4)
- Wilcox JA, Li MJ, Boire AA. Leptomeningeal Metastases: New Opportunities in the Modern Era. Neurotherapeutics. Oct 2022;19(6):1782–1798.
- Adil SM, Hodges SE, Edwards RM, et al. Health care resource utilization and treatment of leptomeningeal carcinomatosis in the United States. Neurooncol Pract. Dec 2020;7(6):636–645.
- Ozair A, Mansouri A, Grossman S. NCTQ-10 INPATIENT CARE COSTS AND ASSOCIATED REIMBURSEMENTS FOR PATIENTS WITH LEPTOMENINGEAL METASTATIC DISEASE: A REAL-WORLD CLAIMS-BASED ANALYSIS. Neurooncol Adv. Aug 2025;7(Suppl 2):ii18–9.
- Derek Ng, PhD, SCM, General Epidemiology and Methodology; 615 N. Wolfe St. Baltimore, MD 21205, Johns Hopkins Bloomberg School of Public Health
- Tom Dang, MBA, MSE, Managing Director; Kaiser Permanente, Division of Research, 4480 Hacienda Dr. Pleasanton, CA 94588
- Dr. Rafit Atum, HSIL Director; T.H. Chan School of Public Health at Harvard University, Research Lab, 651 and 677 Huntington Ave. Boston, MA 0211,
- Gabriel Albors, MS, Senior Project Manager, Research and Operations; Duke-Margolis Institute for Health Policy, 1201 Pennsylvania Ave. Washington, DC 20004.

Scan for contact information

